stockrow
Saturday 7 November 2026
Export XFOR’s income statement to Excel — free account
X4 Pharmaceuticals, Inc.
XFOR Healthcare Biotechnology
X4 Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $35.1 million, up 1,273.2% from fiscal 2024.
- Revenue
- +63.1%
- EPS
- +76.9%
- Free cash flow
- +27.5%
- Total debt
- +1.24%
Quarter to September 2026, against a year earlier
3.15
0.08
+2.61%
Follow XFOR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (80.32%) | (113.08%) | (104.21%) | (75.99%) |
+8 more TTM periods Free account |
|
| (40.73%) | (50.32%) | (49.82%) | (36.25%) | ||
ROIC |
(178.23%) | (226.62%) | (543.03%) | (566.65%) | |
Return on Tangible Assets |
(43.95%) | (45.16%) | (45.67%) | (33.56%) | |
Average Days of Receivables |
31.63 | 47.15 | 45.07 | 5.96 | |
Free Cash Flow per Share |
(0.64) | (0.70) | (0.74) | (2.10) | |
Free Cash Flow |
(81.10) | (88.74) | (92.85) | (88.62) | |
Capital Expenditures |
(5.00) | (5.00) | — | (3.00) | |
| Other line items | |||||
Cash ROIC |
(20.09%) | (20.16%) | (19.40%) | (17.19%) | |
Accounts Receivable Turnover |
11.03 | 8.10 | 7.88 | 30.76 | |
Accounts Payable Turnover |
0.62 | 0.50 | 0.20 | 0.80 | |
Inventory Turnover |
0.65 | 0.68 | 0.42 | 1.58 | |
Average Days of Payables |
576.54 | 490.07 | 1,129.74 | 361.13 | |
Days of Inventory on Hand |
650.08 | 685.40 | 1,032.64 | 283.97 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
367.86% | 418.92% | 772.80% | 207.11% | |
Selling, General and Administrative Expense of Revenue |
187.86% | 217.30% | 393.40% | 123.93% | |
Share Based Compensation of Revenue |
66.46% | 53.83% | 68.69% | 12.24% | |
Interest Coverage |
(9.26) | (10.06) | (11.10) | (9.79) | |
Operating CF/Net income |
0.95 | 0.93 | 0.93 | 1.08 | |
Depreciation/Fixed assets |
31.12 | 15.01 | 7.01 | 7.02 | |
Capex/Depreciation |
(2.82) | (3.00) | 0.00 | (2.35) | |
Revenue per Share |
0.13 | 0.13 | 0.07 | 0.83 | |
Operating CF per Share |
(0.60) | (0.66) | (0.74) | (2.02) | |
Capex per Share |
(0.04) | (0.04) | 0.00 | (0.07) | |
Capex to Sales |
0.29 | 0.32 | 0.00 | 0.09 |
Columns are period end dates · fundamentals updated 6 Nov 2026